GeneDx reported third-quarter 2026 revenue of $123.1 million, up 5% from a year earlier, as growth in exome and genome testing continued. The genetic-testing company also reported higher test volumes and improved adjusted gross margin from the prior quarter, while adjusted net income was below the year-earlier level.
GeneDx reaffirmed its full-year revenue outlook of $475 million to $490 million.
Key details
- Revenue: Total revenue was $123.1 million. Revenue from exome and genome tests reached $110.4 million, up 12% year over year.
- Testing volume: The company reported 32,134 exome and genome test results, a 25% increase from the third quarter of 2025. Accession growth—the increase in tests received for processing—was 28%.
- Margins: Adjusted gross margin was 72%, up from 70% in the second quarter but below 74% a year earlier. GAAP gross margin was 70%.
- Expenses: Adjusted operating expenses were $79.4 million, or 65% of revenue. Total operating expenses under GAAP were $96.5 million.
- Profitability: Adjusted net income was $8.6 million, up $8.2 million from the second quarter. It was below the $16.1 million reported on an adjusted basis a year earlier.
- 2026 outlook: GeneDx reiterated its full-year revenue guidance of $475 million to $490 million.
Plain-English implications
The quarter showed continued growth in testing activity, with exome and genome revenue rising faster than overall revenue. Adjusted gross margin improved sequentially but remained below its year-earlier level, and adjusted net income was also lower than a year ago.